Incyte Corp. (INCY) — Form 8-K: Current report

Incyte Corp. filed a current report on November 13, 2026, announcing it will not proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667 for ovarian cancer. The decision stems from clinical portfolio prioritization rather than safety or efficacy findings. The company stated this determination is not expected to affect its financial guidance or long-term outlook.